Advancing small molecule read through compounds to prevent and/or treat heritable pulmonary artery hypertension
Ended Project Grant Awarded Last action
- Award ID
- R41HL152915
- Recipient
-
Advent Therapeutics Inc. UEI VMY3LNAJHQN9
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $504,262
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- Pennsylvania, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $252,131 | |
| Original award | $252,131 |
Quick answers
Who received award R41HL152915?
R41HL152915 was awarded to Advent Therapeutics Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 15, 2020.
How much is award R41HL152915 worth?
$504,262 has been obligated on R41HL152915.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award